Different sublines of Jurkat cells respond with varying susceptibility of internucleosomal DNA degradation to different mediators of apoptosis.
The ability of two different Jurkat sublines, termed standard and JM, to form DNA ladders was investigated after various apoptotic stimuli. Exposure to a broad spectrum of drugs interfering with signal transduction or cellular metabolism revealed distinct differences between both Jurkat sublines with regard to the pattern of DNA degradation. In standard Jurkat cells, internucleosomal DNA cleavage occurred only after treatment with the protein kinase inhibitor staurosporine. In contrast, the JM subline responded with internucleosomal DNA fragmentation to exposure to gemcitabine, cycloheximide or staurosporine. All drugs induced the formation of DNA fragments of about 50 kb in both sublines, as revealed by pulse field electrophoresis, except H2O2, which caused unspecific DNA degradation. The staurosporine-induced DNA ladder formation was accompanied by an increase in caspase-3 activity in both lines which, however, was considerably lower in Jurkat JM cells after gemcitabine or cycloheximide exposure. When the analysis of internucleosomal DNA degradation was carried out after mycoplasma infection, both Jurkat lines responded with DNA ladder formation after exposure to all drugs used (here only shown for the standard subline). Employing the zymogram technique, nuclease activities of 47 kDa and 54 kDa were detected in culture supernatants, cell homogenates and nuclear extracts only when mycoplasma-infected, whereas the samples obtained from mycoplasma-free sublines were nuclease-negative using this technique, indicating that these endonucleases were of mycoplasmal origin. After drug exposure, the mycoplasmal nucleases must have gained access to the cytoplasm and nuclei of their host cells by an unknown mechanism.
Stolzenberg
I
I
Abteilung für Anatomie und Embryologie, Ruhr-Universität Bochum, Germany.
Wulf
S
S
Mannherz
H G
HG
Paddenberg
R
R
D000906:Antibodies / Q000276:immunology; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D053148:Caspase 3; D020169:Caspases / Q000378:metabolism; D018929:Cell Culture Techniques / Q000379:methods*; D002467:Cell Nucleus / Q000201:enzymology / Q000648:ultrastructure*; D004247:DNA / Q000378:metabolism* / Q000648:ultrastructure; D053938:DNA Fragmentation / Q000187:drug effects*; D003851:Deoxyribonucleases; D006801:Humans; D006861:Hydrogen Peroxide / Q000494:pharmacology; D019169:Jurkat Cells; D009174:Mycoplasma / Q000201:enzymology; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology*; D019311:Staurosporine / Q000494:pharmacology; D019014:fas Receptor / Q000276:immunology
D000906:Antibodies; D000964:Antimetabolites, Antineoplastic; D011500:Protein Synthesis Inhibitors; D019014:fas Receptor; D004247:DNA; D006861:Hydrogen Peroxide; D003851:Deoxyribonucleases; C505407:CASP3 protein, human; D053148:Caspase 3; D020169:Caspases; D019311:Staurosporine